MG29 Modulation for Skeletal Muscle Glucose Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 2, are inadequate in addressing insulin resistance and glucose metabolism defects in skeletal muscle, leading to persistent high blood glucose levels and associated complications.
Innovation Solution
Development of recombinant nucleic acid and polypeptide compositions targeting MG29, a protein critical for glucose metabolism in skeletal muscle, to modulate its expression and activity, thereby enhancing glucose uptake and insulin sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diabetes treatments are used, then general glucose control is achieved, but insulin resistance and glucose metabolism defects in skeletal muscle are not adequately addressed
Solution Approach 1:
The patent uses MG29 as an intermediary target to mediate the effect of therapeutic compositions on glucose metabolism. By modulating MG29 expression or activity, the compositions indirectly improve insulin sensitivity and glucose uptake in skeletal muscle, addressing the harmful effects of insulin resistance that current treatments fail to address adequately.
Solution Approach 2:
The patent changes the parameter of MG29 expression level or activity state through therapeutic compositions. By increasing or modulating MG29 expression in skeletal muscle, the treatment alters the metabolic parameters of glucose uptake and insulin sensitivity, thereby improving the effectiveness of diabetes treatment where conventional approaches have failed.
2Reliability
If MG29 expression is modulated to enhance glucose uptake, then blood glucose levels are lowered and insulin sensitivity is improved, but the complexity of therapeutic intervention increases
Solution Approach 1:
MG29 serves as a specific intermediary molecular target that simplifies the therapeutic approach. Rather than attempting to directly modify complex insulin signaling pathways, the patent focuses on modulating MG29 expression, which naturally mediates glucose uptake. This intermediary approach reduces therapeutic complexity while improving glucose metabolism control.
3Adaptability or versatility
If MG29 is targeted for diabetes treatment, then novel therapeutic efficacy is achieved, but the lack of prior knowledge about MG29 function increases research and development difficulty
Solution Approach 1:
The patent performs preliminary actions by first identifying and characterizing MG29's localization at the triad junction and its potential role in calcium handling and excitation-contraction coupling. This preliminary characterization of MG29 function provides a foundation for subsequent therapeutic development, reducing the research difficulty before clinical application.
Solution Approach 2:
The patent employs feedback mechanisms by measuring changes in glucose uptake, insulin sensitivity, and MG29 expression levels to evaluate therapeutic efficacy. This feedback information guides further optimization of the therapeutic compositions, making the R&D process more manageable despite the novelty of targeting MG29.
Data Source
AI summary
Disclosed herein are compositions and methods for treatment of muscle dysfunction, including diabetes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorders. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.